The endocannabinoid system: a general view and latest additions.
Journal: 2004/October - British Journal of Pharmacology
ISSN: 0007-1188
Abstract:
After the discovery, in the early 1990s, of specific G-protein-coupled receptors for marijuana's psychoactive principle Delta(9)-tetrahydrocannabinol, the cannabinoid receptors, and of their endogenous agonists, the endocannabinoids, a decade of investigations has greatly enlarged our understanding of this altogether new signalling system. Yet, while the finding of the endocannabinoids resulted in a new effort to reveal the mechanisms regulating their levels in the brain and peripheral organs under physiological and pathological conditions, more endogenous substances with a similar action, and more molecular targets for the previously discovered endogenous ligands, anandamide and 2-arachidonoylglycerol, or for some of their metabolites, were being proposed. As the scenario becomes subsequently more complicated, and the experimental tasks to be accomplished correspondingly more numerous, we briefly review in this article the latest 'additions' to the endocannabinoid system together with earlier breakthroughs that have contributed to our present knowledge of the biochemistry and pharmacology of the endocannabinoids.
Relations:
Content
Citations
(74)
References
(99)
Chemicals
(3)
Organisms
(2)
Processes
(1)
Similar articles
Articles by the same authors
Discussion board
Br J Pharmacol 141(5): 765-774

The endocannabinoid system: a general view and latest additions

1Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, Comprensorio Olivetti, Fabbricato 70, 80078 Pozzuoli (Napoli), Italy
2Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, Comprensorio Olivetti, Fabbricato 70, 80078 Pozzuoli (Napoli), Italy
Author for correspondence: ti.rnc.an.bimci@ozramidv
Received 2003 Sep 24; Revised 2003 Oct 9; Accepted 2003 Dec 11.

Abstract

After the discovery, in the early 1990s, of specific G-protein-coupled receptors for marijuana's psychoactive principle Δ-tetrahydrocannabinol, the cannabinoid receptors, and of their endogenous agonists, the endocannabinoids, a decade of investigations has greatly enlarged our understanding of this altogether new signalling system. Yet, while the finding of the endocannabinoids resulted in a new effort to reveal the mechanisms regulating their levels in the brain and peripheral organs under physiological and pathological conditions, more endogenous substances with a similar action, and more molecular targets for the previously discovered endogenous ligands, anandamide and 2-arachidonoylglycerol, or for some of their metabolites, were being proposed. As the scenario becomes subsequently more complicated, and the experimental tasks to be accomplished correspondingly more numerous, we briefly review in this article the latest ‘additions' to the endocannabinoid system together with earlier breakthroughs that have contributed to our present knowledge of the biochemistry and pharmacology of the endocannabinoids.

Keywords: Endocannabinoids, cannabinoid, receptor, anandamide, 2-arachidonoylglycerol, vanilloid, phosphatidic
Abstract

Abbreviations

AEAN-arachidonoyl-ethanolamine (anandamide)
2-AG2-arachidonoyl-glycerol
2-AGE2-arachidonyl-glyceryl ether (noladin)
AMTanandamide membrane transporter
DAGdiacylglycerol
FAAHfatty acid amide hydrolase
GPCRsG-protein-coupled receptors
MAGLsmonoacylglycerol lipase
NADAN-arachidonoyl-dopamine
NAPEN-acyl-phosphatidylethanolamines
NAPE-PLDNAPE-selective PLD
NArPEN-arachidonoyl-phosphatidylethanolamine
PAphosphatidic acid
PIphosphoinositides
PI-PLCPI-selective phospholipase C
PLDphospholipase D
sn-1 DAGLsn-1-selective DAG lipase
THC(-)-Δ-tetrahydrocannabinol
TRPV1transient receptor potential vanilloid type 1 receptor
virhodamineO-arachidonoyl-ethanolamine
Abbreviations
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.